• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在墨西哥一家资源有限的畸形学诊所,将临床全基因组测序作为一线检测手段。

Clinical whole genome sequencing as a first-tier test at a resource-limited dysmorphology clinic in Mexico.

作者信息

Scocchia Alicia, Wigby Kristen M, Masser-Frye Diane, Del Campo Miguel, Galarreta Carolina I, Thorpe Erin, McEachern Julia, Robinson Keisha, Gross Andrew, Ajay Subramanian S, Rajan Vani, Perry Denise L, Belmont John W, Bentley David R, Jones Marilyn C, Taft Ryan J

机构信息

1Illumina, Inc, San Diego, CA 92122 USA.

2Rady's Children's Hospital, San Diego, CA 92123 USA.

出版信息

NPJ Genom Med. 2019 Feb 14;4:5. doi: 10.1038/s41525-018-0076-1. eCollection 2019.

DOI:10.1038/s41525-018-0076-1
PMID:30792901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6375919/
Abstract

Patients with rare, undiagnosed, or genetic disease (RUGD) often undergo years of serial testing, commonly referred to as the "diagnostic odyssey". Patients in resource-limited areas face even greater challenges-a definitive diagnosis may never be reached due to difficulties in gaining access to clinicians, appropriate specialists, and diagnostic testing. Here, we report on a collaboration of the Illumina iHope Program with the Foundation for the Children of the Californias and Hospital Infantil de Las Californias, to enable deployment of clinical whole genome sequencing (cWGS) as first-tier test in a resource-limited dysmorphology clinic in northern Mexico. A total of 60 probands who were followed for a suspected genetic diagnosis and clinically unresolved after expert examination were tested with cWGS, and the ordering clinicians completed a semi-structured survey to investigate change in clinical management resulting from cWGS findings. Clinically significant genomic findings were identified in 68.3% ( = 41) of probands. No recurrent molecular diagnoses were observed. Copy number variants or gross chromosomal abnormalities accounted for 48.8% ( = 20) of the diagnosed cases, including a mosaic trisomy and suspected derivative chromosomes. A qualitative assessment of clinical management revealed 48.8% ( = 20) of those diagnosed had a change in clinical course based on their cWGS results, despite resource limitations. These data suggest that a cWGS first-tier testing approach can benefit patients with suspected genetic disorders.

摘要

患有罕见、未确诊或遗传性疾病(RUGD)的患者通常要经历数年的系列检测,通常被称为“诊断之旅”。资源有限地区的患者面临着更大的挑战——由于难以接触到临床医生、合适的专家以及诊断检测,可能永远无法得到明确的诊断。在此,我们报告了Illumina iHope项目与加利福尼亚儿童基金会及加利福尼亚儿童医院的合作,以便在墨西哥北部一个资源有限的畸形学诊所将临床全基因组测序(cWGS)作为一线检测方法进行应用。共有60名因疑似遗传诊断而接受随访且经专家检查后临床仍未确诊的先证者接受了cWGS检测,开具检测单的临床医生完成了一项半结构化调查,以研究cWGS结果导致的临床管理变化。在68.3%(n = 41)的先证者中发现了具有临床意义的基因组结果。未观察到复发性分子诊断。拷贝数变异或染色体大片段异常占已确诊病例的48.8%(n = 20),包括嵌合三体和疑似衍生染色体。对临床管理的定性评估显示,尽管存在资源限制,但48.8%(n = 20)的确诊患者根据其cWGS结果改变了临床病程。这些数据表明,cWGS一线检测方法可使疑似遗传疾病患者受益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c74/6375919/ebe245d1d60f/41525_2018_76_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c74/6375919/69280858e36f/41525_2018_76_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c74/6375919/ebe245d1d60f/41525_2018_76_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c74/6375919/69280858e36f/41525_2018_76_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c74/6375919/ebe245d1d60f/41525_2018_76_Fig2_HTML.jpg

相似文献

1
Clinical whole genome sequencing as a first-tier test at a resource-limited dysmorphology clinic in Mexico.在墨西哥一家资源有限的畸形学诊所,将临床全基因组测序作为一线检测手段。
NPJ Genom Med. 2019 Feb 14;4:5. doi: 10.1038/s41525-018-0076-1. eCollection 2019.
2
Prospective chromosome analysis of 3429 amniocentesis samples in China using copy number variation sequencing.使用拷贝数变异测序对中国 3429 例羊水穿刺样本进行前瞻性染色体分析。
Am J Obstet Gynecol. 2018 Sep;219(3):287.e1-287.e18. doi: 10.1016/j.ajog.2018.05.030. Epub 2018 May 29.
3
Tissue Specificity in Trisomy 22 Mosaicism: A Tale of Caution for Interpretation of Chromosomal Microarray Results.22号染色体三体嵌合体的组织特异性:解读染色体微阵列结果时需谨慎的案例
J Assoc Genet Technol. 2018;44(4):137-140.
4
Impact of deep phenotyping: high diagnostic yield in a diverse pediatric population of 172 patients through clinical whole-genome sequencing at a single center.深度表型分析的影响:通过单中心临床全基因组测序,在172名不同的儿科患者群体中实现高诊断率。
Front Genet. 2024 Mar 15;15:1347474. doi: 10.3389/fgene.2024.1347474. eCollection 2024.
5
Periodic reanalysis of whole-genome sequencing data enhances the diagnostic advantage over standard clinical genetic testing.全基因组测序数据的定期重新分析增强了其相对于标准临床遗传检测的诊断优势。
Eur J Hum Genet. 2018 May;26(5):740-744. doi: 10.1038/s41431-018-0114-6. Epub 2018 Feb 16.
6
Not the End of the Odyssey: Parental Perceptions of Whole Exome Sequencing (WES) in Pediatric Undiagnosed Disorders.奥德赛之旅尚未结束:父母对儿科未确诊疾病全外显子组测序(WES)的看法。
J Genet Couns. 2016 Oct;25(5):1019-31. doi: 10.1007/s10897-016-9933-1. Epub 2016 Feb 12.
7
Optimized trio genome sequencing (OTGS) as a first-tier genetic test in critically ill infants: practice in China.优化三联体基因组测序(OTGS)作为危重症婴儿的一线基因检测:中国的实践。
Hum Genet. 2020 Apr;139(4):473-482. doi: 10.1007/s00439-019-02103-8. Epub 2020 Jan 21.
8
Whole Genome Sequencing Expands Diagnostic Utility and Improves Clinical Management in Pediatric Medicine.全基因组测序扩大了诊断效用并改善了儿科医学的临床管理。
NPJ Genom Med. 2016 Jan 13;1:15012-. doi: 10.1038/npjgenmed.2015.12.
9
Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center.应用母体外周血游离 DNA 低深度全基因组测序技术进行非侵入性产前检测胎儿染色体非整倍体:单中心 1982 例连续病例的回顾性研究
Ultrasound Obstet Gynecol. 2014 Mar;43(3):254-64. doi: 10.1002/uog.13277. Epub 2014 Feb 10.
10
Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test.重度神经发育障碍的诊断历程:迈向将临床全外显子测序作为一线诊断测试
Clin Genet. 2016 Jun;89(6):700-7. doi: 10.1111/cge.12732. Epub 2016 Apr 26.

引用本文的文献

1
Increasing pathogenic germline variant diagnosis rates in precision medicine: current best practices and future opportunities.提高精准医学中致病种系变异的诊断率:当前最佳实践与未来机遇
Hum Genomics. 2025 Aug 22;19(1):97. doi: 10.1186/s40246-025-00811-z.
2
First-Tier Versus Last-Tier Trio Whole-Genome Sequencing for the Diagnosis of Pediatric-Onset Rare Diseases.一线与末线三重全基因组测序用于诊断儿童期罕见病
Clin Genet. 2025 Oct;108(4):412-421. doi: 10.1111/cge.14760. Epub 2025 Apr 24.
3
Multiple molecular diagnoses identified through genome sequencing in individuals with suspected rare disease.

本文引用的文献

1
Copy-number variants in clinical genome sequencing: deployment and interpretation for rare and undiagnosed disease.临床基因组测序中的拷贝数变异:在罕见病和不明原因疾病中的应用和解读。
Genet Med. 2019 May;21(5):1121-1130. doi: 10.1038/s41436-018-0295-y. Epub 2018 Oct 8.
2
Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test.与靶向基因测序panel 相比,提高了诊断产量,提示全基因组测序作为一线遗传检测具有一定作用。
Genet Med. 2018 Apr;20(4):435-443. doi: 10.1038/gim.2017.119. Epub 2017 Aug 3.
3
Whole Genome Sequencing Expands Diagnostic Utility and Improves Clinical Management in Pediatric Medicine.
通过基因组测序在疑似罕见病个体中鉴定出的多种分子诊断结果。
HGG Adv. 2025 Apr 7;6(3):100430. doi: 10.1016/j.xhgg.2025.100430.
4
Clinical genome sequencing in patients with suspected rare genetic disease in Peru.秘鲁疑似罕见遗传病患者的临床基因组测序
NPJ Genom Med. 2024 Oct 28;9(1):51. doi: 10.1038/s41525-024-00434-8.
5
Reduced Penetrance is Common Among Predicted Loss-of-Function Variants and is Likely Driven by Residual Allelic Activity.预测的功能丧失变异中,降低的外显率很常见,且可能由残余等位基因活性驱动。
medRxiv. 2025 Mar 20:2024.09.23.24314008. doi: 10.1101/2024.09.23.24314008.
6
Integrative genetic analysis: cornerstone of precision psychiatry.整合遗传学分析:精准精神病学的基石
Mol Psychiatry. 2025 Jan;30(1):229-236. doi: 10.1038/s41380-024-02706-2. Epub 2024 Aug 30.
7
Facing the challenges to shorten the diagnostic odyssey: first Whole Genome Sequencing experience of a Colombian cohort with suspected rare diseases.面对缩短诊断探索之旅的挑战:哥伦比亚疑似罕见病队列的首次全基因组测序经验。
Eur J Hum Genet. 2024 Oct;32(10):1327-1337. doi: 10.1038/s41431-024-01609-8. Epub 2024 Jun 22.
8
The impact of clinical genome sequencing in a global population with suspected rare genetic disease.临床基因组测序对疑似罕见遗传病全球人群的影响。
Am J Hum Genet. 2024 Jul 11;111(7):1271-1281. doi: 10.1016/j.ajhg.2024.05.006. Epub 2024 Jun 5.
9
Bayesian cost-effectiveness analysis of Whole genome sequencing versus Whole exome sequencing in a pediatric population with suspected genetic disorders.贝叶斯成本效果分析全基因组测序与全外显子组测序在疑似遗传疾病的儿科人群中的应用。
Eur J Health Econ. 2024 Aug;25(6):999-1011. doi: 10.1007/s10198-023-01644-0. Epub 2023 Nov 17.
10
Physician services and costs after disclosure of diagnostic sequencing results in the NYCKidSeq program.公布 NYCKidSeq 项目诊断测序结果后的医师服务和费用。
Genet Med. 2024 Jan;26(1):101011. doi: 10.1016/j.gim.2023.101011. Epub 2023 Oct 27.
全基因组测序扩大了诊断效用并改善了儿科医学的临床管理。
NPJ Genom Med. 2016 Jan 13;1:15012-. doi: 10.1038/npjgenmed.2015.12.
4
A reference data set of 5.4 million phased human variants validated by genetic inheritance from sequencing a three-generation 17-member pedigree.通过对一个包含17名成员的三代家系进行测序,经遗传继承验证的540万个定相人类变异的参考数据集。
Genome Res. 2017 Jan;27(1):157-164. doi: 10.1101/gr.210500.116. Epub 2016 Nov 30.
5
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.临床外显子组和基因组测序中次要发现报告的建议,2016年更新版(美国医学遗传学与基因组学学会次要发现v2.0):美国医学遗传学与基因组学学会政策声明
Genet Med. 2017 Feb;19(2):249-255. doi: 10.1038/gim.2016.190. Epub 2016 Nov 17.
6
Clinical exome sequencing: results from 2819 samples reflecting 1000 families.临床外显子组测序:来自反映1000个家庭的2819份样本的结果。
Eur J Hum Genet. 2017 Feb;25(2):176-182. doi: 10.1038/ejhg.2016.146. Epub 2016 Nov 16.
7
Canvas: versatile and scalable detection of copy number variants.Canvas:灵活且可扩展的拷贝数变异检测。
Bioinformatics. 2016 Aug 1;32(15):2375-7. doi: 10.1093/bioinformatics/btw163. Epub 2016 Mar 24.
8
Clinical sequencing: is WGS the better WES?临床测序:全基因组测序是否比全外显子组测序更好?
Hum Genet. 2016 Mar;135(3):359-62. doi: 10.1007/s00439-015-1631-9. Epub 2016 Jan 7.
9
Global burden of genetic disease and the role of genetic screening.全球遗传疾病负担及基因筛查的作用。
Semin Fetal Neonatal Med. 2015 Oct;20(5):354-63. doi: 10.1016/j.siny.2015.07.002. Epub 2015 Aug 4.
10
GeneMatcher: a matching tool for connecting investigators with an interest in the same gene.基因匹配器:一种用于将对同一基因感兴趣的研究人员联系起来的匹配工具。
Hum Mutat. 2015 Oct;36(10):928-30. doi: 10.1002/humu.22844. Epub 2015 Aug 13.